EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

[cafead]

via The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris, but Novartis’ iptacopan could provide an oral option after positive phase 2 trial results.

article source